EMA CHMP issues positive opinion for AstraZeneca’s Soliris
The EMA CHMP has issued a positive opinion recommending marketing authorisation for expanded use of AstraZeneca’s Soliris (eculizumab).
The EMA CHMP has issued a positive opinion recommending marketing authorisation for expanded use of AstraZeneca’s Soliris (eculizumab).
What's Your Reaction?
